Waylivra (volanesorsen)
Waylivra (volanesorsen) Uses, Dosage, Side Effects, Food Interaction and all others data.
Waylivra (volanesorsen) is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation. It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons. This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.
Waylivra (volanesorsen) was granted a conditional approval by the European Medicines Agency.
Waylivra (volanesorsen) is an antisense oligonucleotide that prevents the translation of apoC-III. It has a long duration of action as it has a half life of >2 weeks. Patients should be counselled regarding the risk of thrombocytopenia, raised LDL-C levels, renal toxicity, hepatotoxicity, and immunogenicity.
| Trade Name | Waylivra (volanesorsen) |
| Generic | Volanesorsen |
| Volanesorsen Other Names | Volanesorsen |
| Type | Injection |
| Protein binding | Volanesorsen is >98% bound to proteins in plasma. Though the exact proteins have not been identified. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Akcea Therapeutics UK Ltd |
| Available Country | United Kingdom |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Waylivra (volanesorsen) is an antisense oligonucleotide indicated to treat familial chylomicronemia.
Waylivra (volanesorsen) is conditionally approved by the EMA as an adjunct to diet in adults with familial chylomicronemia, at high risk for pancreatitis, and who have had an inadequate response to diet and triglyceride lowering therapy.
Waylivra (volanesorsen) is also used to associated treatment for these conditions: Familial Chylomicronemia
How Waylivra (volanesorsen) works
Waylivra (volanesorsen) is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation, and preventing translation of apoC-III protein. Normally, apoC-III would inhibit triglyceride metabolism and hepatic clearance of chylomicrons. Preventing translation of apoC-III allows for metabolism and breakdown of these triglycerides and chylomicrons.
Toxicity
Data regarding overdose are not readily available. However, symptoms are likely to involve injection site reactions and constitutional symptomns. Treat patients with symptomatic and supportive care.
Food Interaction
No interactions found.Volume of Distribution
The volume of distribution at steady state is 330 L in patients with familial chylomicronemia.
Elimination Route
Waylivra (volanesorsen) is approximately 80% bioavailable. A 285mg dose given weekly reaches a Cmax of 8.92 µg/mL, with an AUC of 136 µg*h/mL.
Half Life
Waylivra (volanesorsen) has a half life of >2 weeks.
Clearance
The exact rate of clearance of volanesorsen is unknown, however it is rapidly distributed to tissues and very slowly eliminated.
Elimination Route
Waylivra (volanesorsen) is predominantly eliminated in the urine, though 2
Innovators Monograph
You find simplified version here Waylivra (volanesorsen)
